ASCO 2015

Enzalutamide May Represent Novel Therapeutic Option for Triple-Negative Breast Cancer

Enzalutamide May Represent Novel Therapeutic Option for Triple-Negative Breast Cancer

By

Enzalutamide may be a viable alternative therapy over cytotoxic chemotherapy for individuals with triple-negative breast cancer, according to a study presented at the 2015 American Society of Clinical Oncology annual meeting.

Persistent HPV16 in Oral Rinses Signals Poor Prognosis for HPV-Positive Oropharyngeal Carcinoma

Persistent HPV16 in Oral Rinses Signals Poor Prognosis for HPV-Positive Oropharyngeal Carcinoma

By

Detection of human papillomavirus (HPV)16 DNA in oral rinses following treatment for HPV-positive oropharyngeal carcinoma could be a potential tool for long-term tumor surveillance, a study concluded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

Adapting Pediatric Cancer Treatments to Spur Early Detection and Reduce Late Effects

Adapting Pediatric Cancer Treatments to Spur Early Detection and Reduce Late Effects

By

Modifying pediatric cancer treatments may reduce occurrence of late effects and promoting early detection, indicated data from a 5-year analysis of childhood cancers survivors presented at ASCO 2015.

Radiosurgery and Careful Monitoring Combo Recommended for Newly Diagnosed Brain Metastases

Radiosurgery and Careful Monitoring Combo Recommended for Newly Diagnosed Brain Metastases

By

Radiosurgery and close monitoring is recommended to better preserve cognitive function in newly diagnosed brain metastases.

Elective Neck Dissection Recommended Standard of Care for Early Oral Cancer

Elective Neck Dissection Recommended Standard of Care for Early Oral Cancer

By

Elective neck dissection in clinically node-negative early oral squamous cell carcinoma should be considered the standard of care.

Nivolumab Yields Better Clinical Outcomes for Advanced Melanoma

Nivolumab Yields Better Clinical Outcomes for Advanced Melanoma

By

Treatment-naïve patients with advanced melanoma had significantly better clinical outcomes with nivolumab alone or in combination with ipilimumab.

PET-CT Surveillance Cost-Effective for Locally Advanced Head and Neck Squamous Cell Cancer

PET-CT Surveillance Cost-Effective for Locally Advanced Head and Neck Squamous Cell Cancer

By

PET-CT guided active surveillance for patients with locally advanced head and neck squamous cell cancer is an option over node dissection, per analysis data presented at the 2015 American Society of Clinical Oncology annual meeting.

Pembrolizumab Active in Advanced Gastric Cancer

Pembrolizumab Active in Advanced Gastric Cancer

By

The anti-PD-1 monoclonal antibody, pembrolizumab (MK-3475), demonstrated promising antitumor activity in advanced gastric cancer, according to a study presented at the 2015 ASCO Annual Meeting.

Aspirin Exposure after Colorectal Cancer Diagnosis Associated with Improved Survival

Aspirin Exposure after Colorectal Cancer Diagnosis Associated with Improved Survival

By

Aspirin exposure after a colorectal cancer diagnosis was independently associated with improved colorectal cancer-specific survival.

Nivolumab Demonstrates Consistent Adverse Event Profile for Recurrent Glioblastoma

Nivolumab Demonstrates Consistent Adverse Event Profile for Recurrent Glioblastoma

By

The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.

Addition of SIRT Fails to Improve Overall Progression-free Survival in Colorectal Cancer Liver Metastases

Addition of SIRT Fails to Improve Overall Progression-free Survival in Colorectal Cancer Liver Metastases

By

Addition of selective internal radiation therapy (SIRT) failed to improve progression-free survival in non-resectable colorectal cancer liver metastases.

Combination of mFOLFOX6 and Radiotherapy Yields Higher pCR in Rectal Cancer

Combination of mFOLFOX6 and Radiotherapy Yields Higher pCR in Rectal Cancer

By

mFOLFOX6 administered concurrently with radiation therapy resulted in a higher pathological complete response in rectal cancer.

Higher Vitamin D Concentrations Associated with Improved Survival in mCRC

Higher Vitamin D Concentrations Associated with Improved Survival in mCRC

By

In patients with metastatic colorectal cancer treated with chemotherapy plus biologics, increased vitamin D levels have been linked to improved survival, according to information presented at the ASCO 2015 Annual Meeting.

Narrow Excision Margins in High Risk Primary Melanoma Associated with Higher Cancer-Related Death

Narrow Excision Margins in High Risk Primary Melanoma Associated with Higher Cancer-Related Death

By

Higher mortality is associated with more narrow margins for high-risk primary melanoma, per research presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago.

RFA Plus Chemo Associated with Improved Survival in Unresectable Colorectal CA Liver Metastases

RFA Plus Chemo Associated with Improved Survival in Unresectable Colorectal CA Liver Metastases

By

A combination of radiofrequency ablation and systemic chemotherapy was associated with improved long-term overall survival in patients with unresectable colorectal cancer liver metastases, according to data presented at the 2015 American Society of Clinical Oncology annual meeting.

Internationally Applicable Prognostic Index for 5-Year OS Validated for Patients with CLL

Internationally Applicable Prognostic Index for 5-Year OS Validated for Patients with CLL

By

A new meta-analysis of 26 factors has resulted in an internationally applicable prognostic index for patients with chronic lymphocytic leukemia, according to study results presented at 2015 ASCO Annual Meeting.

Optimal Sequencing for Chemotherapy and Radium 223 for Prostate Cancer Under Debate

Optimal Sequencing for Chemotherapy and Radium 223 for Prostate Cancer Under Debate

By

When is chemotherapy or radium 223 the optimal treatment for men with advanced prostate cancer?

Removing the Obstacles Associated With Survivorship Care

Removing the Obstacles Associated With Survivorship Care

By

As of 2012 in the U.S. there were 14 million cancer survivors, a number that is expected to grow to 18 million by 2022.

MEDI4736 Shows Consistent Safety Response in Head and Neck Squamous Cell Carcinoma

MEDI4736 Shows Consistent Safety Response in Head and Neck Squamous Cell Carcinoma

By

Safety profile of MEDI4736 in patients with squamous cell carcinoma of the head and neck is manageable.

Pembrolizumab and Ipilimumab Combo Safe for Melanoma and Renal Cell Carcinoma

Pembrolizumab and Ipilimumab Combo Safe for Melanoma and Renal Cell Carcinoma

By

Pembrolizumab plus low-dose ipilimumab combination considered to have an acceptable safety profile in melanoma or renal cell carcinoma.

Ongoing Phase IIIb/IV Trial Shows Consistent Safety Data with Nivolumab in NSCLC

Ongoing Phase IIIb/IV Trial Shows Consistent Safety Data with Nivolumab in NSCLC

By

Patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab demonstrated tolerability consistent with prior trails, according to data from a phase IIIb/IV trial presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.

Diagnostic Assay Improves Outcomes Prediction in Early Breast Cancer, Nixing Need for Chemo

Diagnostic Assay Improves Outcomes Prediction in Early Breast Cancer, Nixing Need for Chemo

By

Outcome prediction for postmenopausal patients with node-positive HR+ early breast cancer can be improved using a diagnostic assay, potentially negating the need for adjuvant chemotherapy, according to a study presented at ASCO 2015.

Letrozole Significantly Reduces Late Invasive Events in HR+ Early Breast Cancer

Letrozole Significantly Reduces Late Invasive Events in HR+ Early Breast Cancer

By

Letrozole significantly reduced the rate of late invasive breast cancer events in postmenopausal women who had completed 4+ years of adjuvant endocrine therapy for HR+ breast cancer, the LATER trial concluded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

Young Women with Breast Cancer on Ovarian Suppression Need Early Intervention to Mitigate Poor QOL

Young Women with Breast Cancer on Ovarian Suppression Need Early Intervention to Mitigate Poor QOL

By

Early intervention should be offered to young women with breast cancer on ovarian function suppression and tamoxifen, who experience poorer quality of life (QOL) in the early survivorship period, according to a study presented at the 2015 American Society of Clinical Oncology Annual Meeting.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs